Skip to content

Clinical trials

Neurocognitive Disorders trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neurocognitive Disorders Clear all

252 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20031
20061
20072
20081
20091
20101
20115
20126
20133
20146
20157
201610
201716
201817
201921
202018
202122
202226
202329
202418
202521
202618

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed98
Recruiting46
Unknown status45
Terminated22
Active, not recruiting17
Not yet recruiting16
Enrolling by invitation3
Suspended2
Withdrawn2
No longer available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Centre Hospitalier Universitaire de Nice6
Hospices Civils de Lyon6
Rsocialform - Geriatria, Lda6
Eli Lilly and Company4
University of Michigan4
University of Pennsylvania4
Alkahest, Inc.3
Chinese Academy of Medical Sciences, Fuwai Hospital3
Jewish General Hospital3
New York State Psychiatric Institute3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neurocognitive Disorders252
Cognitive Dysfunction83
Dementia81
Alzheimer Disease72
Mental Disorders50
Nervous System Diseases45
Brain Diseases42
Neurodegenerative Diseases39
Central Nervous System Diseases37
Cognition Disorders25

Trials

Showing 1 to 25 of 252. Each trial links to its page on Pharma Observatory.

152 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.